By otakuyassine3@gmail.com 
uniQure (NASDAQ:QURE – Get Free Report) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 3,390,000 shares, a decrease of 21.2% from the December 15th total of 4,300,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 1.6 days.
uniQure Price Performance
NASDAQ QURE traded down $0.16 during trading hours on Friday, hitting $14.05. The company had a trading volume of 994,420 shares, compared to its average volume of 1,365,092. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $684.80 million, a price-to-earnings ratio of -2.83 and a beta of 0.41. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The firm has a 50 day simple moving average of $12.09 and a 200 day simple moving average of $8.35.
uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities research analysts expect that uniQure will post -3.74 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus raised their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $33.88.
Get Our Latest Analysis on uniQure
Insider Activity
In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.74% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. RTW Investments LP bought a new stake in uniQure during the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. boosted its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc purchased a new position in shares of uniQure during the third quarter worth about $53,000. Quarry LP bought a new position in shares of uniQure in the third quarter worth approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC raised its stake in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.
Featured Articles
Receive News & Ratings for uniQure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for uniQure and related companies with MarketBeat.com’s FREE daily email newsletter.